Comparison of the Effect of Warfarin and Direct Oral Anticoagulants

Comparison of the Effect of Warfarin and Direct Oral Anticoagulants on Upper Gastrointestinal System Bleeding

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT06269302

Enrollment

346

Registered

2024-02-21

Start date

2022-01-01

Completion date

2022-12-31

Last updated

2024-02-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anticoagulants and Bleeding Disorders, Gastrointestinal Hemorrhage

Keywords

Gastrointestinal System, Oral Anticoagulant, Rebleeding, upper gastrointestinal system bleeding

Brief summary

In this study, it was aimed to compare the frequency of new oral anticoagulants and warfarin usage, and to reveal the rates of recurrent upper gastrointestinal bleeding among patients who applied to our hospital with upper gastrointestinal bleeding

Detailed description

The data of all patients who applied to Samsun Training and Research Hospital Internal Medicine with a diagnosis of upper gastrointestinal bleeding and hospitalized by Internal Medicine and Gastroenterology clinics or who underwent outpatient endoscopy between 01.01.2021 and 31.12.2021 were included. The patients' data were analyzed from the patient files and hospital automation system retrospectively. Patients who had recurrent upper GI bleeding were detected by controlling them over the hospital software system and by reaching each patient again. The frequency of the new generation oral anticoagulants usage in patients with re-bleeding was determined, and data such as re-bleeding rate, length of hospital stay, need for transfusion, and mortality were analyzed in the groups who did not use this drug and those who used it. The patient demographics were also compared between the groups who were using the new generation oral anticoagulants, acetylsalicylic acid or warfarin.

Interventions

None listed

Study design

Observational model

OTHER

Time perspective

CROSS_SECTIONAL

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Age \>18 years old * Upper gastrointestinal bleeding * 12 months follow-up

Exclusion criteria

* Age \<18 years old * Lower gastrointestinal bleeding * Esophageal variceal bleeding

Design outcomes

Primary

Measure	Time frame	Description
Change in the incidence of recurrent bleeding	12 months	Increase or decrease in the incidence of recurrent bleeding

Countries

Turkey (Türkiye)

Outcome results